Highlight
This study evaluates the impact of baseline cytogenetic abnormalities on clinical outcomes in multiple myeloma patients who achieve stringent measurable residual disease (MRD) negativity after autologous stem cell transplantation (ASCT). Key findings include:
1. Despite uniform MRD negativity, patients harboring certain high-risk cytogenetic abnormalities (HRCAs) experience notably poorer progression-free survival (PFS).
2. Isolated del(17p) and 1q21+ abnormalities confer inferior prognosis.
3. The burden of having multiple HRCAs correlates with further diminished PFS.
4. These observations emphasize persistent high-risk biological behavior after ASCT, underscoring the need for ongoing risk stratification beyond MRD metrics.
Study Background
Multiple myeloma is a hematologic malignancy characterized by clonal proliferation of plasma cells in the bone marrow. Treatment advances, including autologous stem cell transplantation (ASCT), have markedly improved outcomes. MRD assessment by highly sensitive methods now serves as a crucial prognostic and therapeutic benchmark. Achieving MRD negativity is strongly associated with improved survival and guides risk-adapted treatment algorithms. However, the heterogeneous genetic landscape of myeloma, particularly high-risk cytogenetic abnormalities (HRCAs) such as del(17p), 1q21 amplification, and translocations involving IgH loci, confers variable prognosis. The persistence of high-risk biology post-ASCT despite MRD negativity is not fully understood. Clarifying how individual and combined HRCAs impact clinical trajectories after deep remission is essential for optimizing patient management and tailoring maintenance or consolidation strategies.
Study Design
This retrospective cohort study examined 351 newly diagnosed multiple myeloma patients who underwent ASCT and achieved MRD negativity between day 60 and 100 post-transplant. MRD sensitivity reached 2.4 × 10-6, reflecting a highly stringent threshold. Baseline cytogenetic profiling by fluorescence in situ hybridization (FISH) allowed stratification into standard risk, single HRCA, and multiple HRCA groups. Patients were followed for a median of 50.4 months to evaluate progression-free survival (PFS). The analysis compared PFS outcomes based on cytogenetic risk groups within the uniformly MRD-negative cohort.
Key Findings
The study population comprised 46% standard-risk cytogenetics (n=162), 34% with one HRCA (n=118), and 20% with ≥2 HRCAs (n=71). Despite all patients achieving MRD negativity, important differences in PFS emerged:
1. Impact of Individual HRCAs:
– Del(17p) was associated with a significantly reduced 4-year PFS of 56% compared to 84% in the standard-risk group (Hazard Ratio [HR] 2.89; p=0.0001).
– 1q21 amplification (1q21+) similarly conferred a lower 4-year PFS of 60% (HR 2.46; p=0.0001).
– The t(4;14) translocation showed an even poorer outcome with 4-year PFS at 43% (HR 3.50; p=0.0001).
– MAF family translocations (t(14;16)/t(14;20)) were linked to a 4-year PFS of 58% (HR 2.51; p=0.01).
Isolated del(17p) and 1q21+ abnormalities independently predicted inferior PFS outcomes, underscoring their robust prognostic weight.
2. Effect of HRCA Burden:
– Patients harboring one HRCA had a 4-year PFS of 65%, significantly lower than the standard-risk group (HR 2.31; p=0.0004).
– Those with two or more HRCAs experienced a further decline, with a 4-year PFS of 55% (HR 2.75; p=0.0001).
These findings demonstrate that even in the context of deep remission as reflected by MRD negativity, high-risk genetic features continue to influence disease progression. The data argue against relying solely on MRD status for risk assessment post-ASCT and advocate for integrating cytogenetic profiling into ongoing patient management.
Expert Commentary
This robust study by Mariotti and colleagues provides important insight into the biological complexity of multiple myeloma remission post-ASCT. Although MRD negativity is often celebrated as a surrogate for clinical cure, this investigation highlights that intrinsic high-risk cytogenetic lesions can subvert long-term disease control. The durability of MRD negativity in myeloma is not uniform and is significantly shaped by underlying genetic risk. These results echo previous reports linking del(17p), 1q21+, and IgH translocations to aggressive disease biology and inferior outcomes but importantly extend them by demonstrating persistence of risk despite deep molecular response.
Some limitations include the retrospective design and lack of granularity regarding maintenance therapies, which could influence PFS. Additional studies are needed to clarify whether intensified or novel post-transplant interventions can mitigate the adverse impact of HRCAs in MRD-negative patients. Functional studies interrogating the mechanisms by which these cytogenetic lesions promote resistance or relapse would also enrich the translational relevance.
Clinicians should recognize that MRD negativity is necessary but not sufficient to declare remission in patients with high-risk cytogenetics. Risk-adapted therapeutic paradigms that incorporate both MRD and cytogenetic information are essential to optimize survival outcomes in multiple myeloma.
Conclusion
This large cohort study demonstrates that high-risk cytogenetic abnormalities continue to define clinical trajectories and adverse progression outcomes in multiple myeloma patients who achieve MRD negativity after ASCT. The persistence of inferior PFS related to del(17p), 1q21+, t(4;14), and MAF translocations indicates that high-risk biological features endure beyond early molecular remission. These findings underscore the importance of comprehensive cytogenetic assessment alongside sensitive MRD testing to inform prognosis and guide personalized post-transplant management strategies. Future research should focus on tailored maintenance approaches and novel therapies targeting high-risk clones to improve long-term outcomes.
Funding and ClinicalTrials.gov
The original study’s funding sources and clinical trial registration were not specified in the abstract. Readers are encouraged to consult the original publication in Leukemia for detailed disclosures.
References
1. Mariotti EG, Kumar S, Gonsalves W, et al. Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma. Leukemia. 2026 Jul 21. PMID: 42481797.
2. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification, and management. Am J Hematol. 2020;95(5):548-567.
3. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28-35.
4. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210-21.
